CAPTRUST Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22.7M | Sell |
36,464
-2,038
| -5% | -$1.39M | 0.03% | 357 |
|
|
2026
Q1 | $29.7M | Buy |
38,502
+17,323
| +82% | +$13.3M | 0.05% | 284 |
|
|
2025
Q4 | $16.3M | Buy |
21,179
+6,762
| +47% | +$4.59M | 0.03% | 384 |
|
|
2025
Q3 | $8.11M | Buy |
14,417
+3,694
| +34% | +$2.09M | 0.02% | 520 |
|
|
2025
Q2 | $5.63M | Sell |
10,723
-3,565
| -25% | -$1.99M | 0.01% | 591 |
|
|
2025
Q1 | $9.06M | Buy |
14,288
+4,372
| +44% | +$3.01M | 0.02% | 452 |
|
|
2024
Q4 | $7.06M | Buy |
9,916
+786
| +9% | +$660K | 0.02% | 459 |
|
|
2024
Q3 | $9.6M | Buy |
9,130
+296
| +3% | +$329K | 0.03% | 390 |
|
|
2024
Q2 | $9.29M | Sell |
8,834
-65
| -0.7% | -$63K | 0.03% | 368 |
|
|
2024
Q1 | $8.56M | Sell |
8,899
-3,645
| -29% | -$3.47M | 0.03% | 371 |
|
|
2023
Q4 | $11M | Buy |
12,544
+83
| +0.7% | +$68.3K | 0.04% | 351 |
|
|
2023
Q3 | $10.3M | Buy |
12,461
+387
| +3% | +$304K | 0.04% | 333 |
|
|
2023
Q2 | $8.68M | Sell |
12,074
-328
| -3% | -$253K | 0.03% | 358 |
|
|
2023
Q1 | $10.2M | Sell |
12,402
-271
| -2% | -$204K | 0.04% | 293 |
|
|
2022
Q4 | $9.14M | Buy |
12,673
+1,204
| +10% | +$888K | 0.05% | 308 |
|
|
2022
Q3 | $7.9M | Buy |
11,469
+822
| +8% | +$517K | 0.05% | 305 |
|
|
2022
Q2 | $6.29M | Buy |
10,647
+1,189
| +13% | +$773K | 0.04% | 328 |
|
|
2022
Q1 | $6.61M | Sell |
9,458
-446
| -5% | -$282K | 0.04% | 305 |
|
|
2021
Q4 | $6.25M | Buy |
9,904
+3,375
| +52% | +$2.08M | 0.04% | 313 |
|
|
2021
Q3 | $3.95M | Buy |
6,529
+4,636
| +245% | +$2.88M | 0.03% | 369 |
|
|
2021
Q2 | $1.06M | Buy |
1,893
+4
| +0.2% | +$2.03K | 0.01% | 700 |
|
|
2021
Q1 | $894K | Buy |
1,889
+30
| +2% | +$14.6K | 0.01% | 736 |
|
|
2020
Q4 | $898K | Sell |
1,859
-261
| -12% | -$141K | 0.01% | 644 |
|
|
2020
Q3 | $1.2M | Buy |
2,120
+432
| +26% | +$262K | 0.02% | 453 |
|
|
2020
Q2 | $1.03M | Buy |
1,688
+192
| +13% | +$109K | 0.02% | 491 |
|
|
2020
Q1 | $743K | Buy |
1,496
+761
| +104% | +$314K | 0.02% | 480 |
|
|
2019
Q4 | $274K | Buy |
735
+527
| +253% | +$177K | ﹤0.01% | 873 |
|
|
2019
Q3 | $58K | Buy |
208
+126
| +154% | +$37.3K | ﹤0.01% | 946 |
|
|
2019
Q2 | $26K | Buy |
82
+25
| +44% | +$8.32K | ﹤0.01% | 1201 |
|
|
2019
Q1 | $23K | Sell |
57
-23
| -29% | -$9.47K | ﹤0.01% | 1131 |
|
|
2018
Q4 | $30K | Buy |
+80
| New | +$29.3K | ﹤0.01% | 901 |
|
|
2018
Q1 | – | Sell |
-5
| Closed | -$2K | – | 1368 |
|
|
2017
Q4 | $2K | Buy |
+5
| New | +$2.02K | ﹤0.01% | 1186 |
|
Other funds holding REGN
CAPTRUST Financial Advisors's REGN Position: Q2 2026 in Review
CAPTRUST Financial Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 5.3% in Q2 2026, selling an estimated $1.39M and leaving 36,464 shares worth $22.7M. The position accounts for 0.03% of the portfolio, ranked #357.
CAPTRUST Financial Advisors first reported a position in REGN in Q4 2017 and has held it in 32 quarters since. The position peaked at $29.7M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- CAPTRUST Financial Advisors held 36,464 shares of Regeneron Pharmaceuticals worth $22.7M as of Q2 2026.
- CAPTRUST Financial Advisors sold 2,038 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.39M.
- Regeneron Pharmaceuticals made up 0.03% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #357 holding.
- CAPTRUST Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 32 quarters since.
- CAPTRUST Financial Advisors's Regeneron Pharmaceuticals position peaked at $29.7M in Q1 2026.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.